{"word_count": 241, "character_count": 1677}
Le 20 juin 2018 Boris Hauray est invité à l'Université de Tokyo à l'occasion du 66th STIG PoP Seminar. Il présentera une communication intitulée Transparency mechanisms and conflict of interest regulation. The case of pharmaceuticals.Abstract : For more than two decades, conflict of interest controversies have rocked the field of pharmaceuticals and have undermined trust in scientific knowledge, prescription practices and public regulation. The establishment (or reinforcement) of policies aimed at disclosing the financial ties between pharmaceutical firms on the one side, and researchers, experts, administrative and political officials, healthcare professionals or patient organisations on the other, has been the main response to this political and scientific issue. Dr Hauray’s presentation will question the capacity of these “transparency mechanisms” to provide an answer to the growing concern about the influence of pharmaceutical firms over research in medicine.First, it will provide a brief history of conflict of interest disclosure policies in the domain of pharmaceuticals and identify the main properties of transparency brought forward to justify their adoption. It will then analyse the political dynamics explaining the adoption in 2011 in France of a law creating an online public database of the financial relationships between healthcare-related manufacturing companies and the other actors of the sector. Finally, it will discuss the conflicts and doubts raised by the implementation of this law, and examine its first effects on the relationships between healthcare professionals and industry, but also on social mobilisation and the public debate.